Chiron Concludes Phase III Program for Menjugate Meningococcal C Vaccine in United States

Article

EMERYVILLE, Calif. -- Chiron Corporation announced that it has successfully concluded its Phase III trial for Menjugate® meningococcal C vaccine in the United States and will not be filing a Biologics License Application (BLA) for the vaccine. The now-completed Phase III trial in the United States expanded the safety and immunogenicity database for Menjugate, a conjugated vaccine.

Given the changing landscape for meningococcal vaccines in the United States, we believe that our resources are better deployed by focusing on advancing our quadravalent vaccine candidate for serogroups A, C, W and Y, said John Lambert, president, Chiron Vaccines. We have learned a great deal from the Phase III study of Menjugate, and we will apply that experience to move our ACWY vaccine candidate through development.

Chirons meningococcal ACWY vaccine is currently in Phase II. The company initiated a Phase II study in infants this year and plans to initiate a Phase III program for the vaccine in 2005.

Source: Chiron

Newsletter

Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.

Recent Videos
David J. Weber, MD, MPH, president of the Society for Healthcare Epidemiology of America
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
Brenna Doran PhD, MA, hospital epidemiology and infection prevention for the University of California, San Francisco, and a coach and consultant of infection prevention; Jessica Swain, MBA, MLT, director of infection prevention and control for Dartmouth Health in Lebanon, New Hampshire; and Shanina Knighton, associate professor at Case Western Reserve University School of Nursing and senior nurse scientist at MetroHealth System in Cleveland, Ohio
© 2025 MJH Life Sciences

All rights reserved.